AstraZeneca (AZN) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

AstraZeneca Withdraws Lung Cancer Drug Application in EU
TipRanks11:27 ET
AZN, Daiichi Withdraw EU Filing for Dato-DXd in Nonsquamous NSCLC
Zacks Dec 26 09:35 ET
Achievements and Progress Heading Into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
GlobeNewswireDec 26 09:00 ET
AstraZeneca's (LON:AZN) Investors Will Be Pleased With Their Respectable 55% Return Over the Last Five Years
Yahoo FinanceDec 26 01:13 ET
ROSEN, LEADING INVESTOR COUNSEL Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AZN
newsfileDec 25 21:55 ET
AstraZeneca (AZN) Faces Securities Class Action After Reports of PRC Probe Into Fraud and Corruption - Hagens Berman
newsfileDec 25 12:03 ET

Comments

Meltyy

Dec 17 01:56

📌 1 PDUFA this weekand 6 more upcoming this month! 🚀

🔔 This Week’s PDUFA:
$Ionis Pharmaceuticals (IONS.US)$ : 🤔
⇨ IONIS-APOCIII-LRx (Olezarsen)
‣ FCS (Familial chylomicronemia syndrome)
‣ PDUFA: 12/19/24 (NDA)
🗓️ Last Week’s PDUFA Decisions:
$Checkpoint Therapeutics (CKPT.US)$ : Approved 12/13/24 ✅
⇨ UNLOXCYT (cosibelimab-ipdl)
‣ metastatic or locally advanced cSCC (cutaneous squamous cell carcinoma)
‣ PDUFA: 12/28/24 (resubmitted BLA)
$Neurocrine Biosciences (NBIX.US)$ : Approved 12/13/24 ✅
⇨ CRENESSITY™ (crin...

3

10xStockPicks

Dec 15 18:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

10

2

4

10xStockPicks

Dec 15 15:56

Buying This Takeover Target Offers 10X Upside. Esperion Therapeutics.

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...